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superiority in terms of safety and efficacy among drugs. This bulletin intends to
improve health care efficiency when it points out the differences on treatment
costs among the drugs. The objective of this study is to analyze all editions of The
Health and Economics Bulletin available onANVISAwebsite.METHODS:Datawere
collected from editions of Health and Economics Bulletin published since August
2009 (month of launch) until January 2012. The variables considered were: number
and type of diseases, therapeutic classes, active substance, drugs and treatment
costs. RESULTS: Seven editions of the bulletin were published and each number
addressed a different disease such as osteoporosis, glaucoma, gastroesophageal
reflux, arterial hypertension, epilepsy, dyslipidemia and erectile dysfunction. In
total, 11 therapeutic classes were evaluated which comprises biphosphonates and
statins on osteoporoses and dyslipidemia editions, respectively. A total of 27 active
substances and 51 drugs were assessed, including generics, similars and brand
drugs. Fifty-one costs of treatment were performed which demonstrated consid-
erable differences between drugs prescribed for the same disease. For example, on
the arterial hypertension edition, it was found 1811% of difference on treatment
costs between the most expensive and the lowest cost drugs although they have
similar safety and efficacy levels, based on scientific evidences. CONCLUSIONS:
The Health and Economics Bulletin is an important information tool and was elab-
orated to improve the critical view of health care decision-makers and patients.
Considering differences of treatment costs among drugs that have the same safety
and efficacy, they can select the drugs more efficiently.
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OBJECTIVES: Fewer than 100 US hospitals have all-inclusive hybrid operating room
(HOR) suites (ECRI, 2010), although this is increasing at a current annual growth rate
(CAGR) of 15% (Hankel, 2011). The benefits inherent in utilization of the hybrid
approach are substantial, yet remain largely theoretical, given the limited preva-
lence of HORs. Recent HOR technological innovations, including significant im-
provements in image quality, greater detector flexibility and angulation, and better
mobile and floor-mounting options, have driven demand for clinical and economic
data to support the initial investment required. In this study, we reviewed existing
literature on the clinical and economic value offered by HOR suites. METHODS: A
systematic review of peer reviewed literature published between 2006 and 2011
was conducted. Descriptions of the clinical, economic, and workflow benefits of
HOR programs were incorporated into the review. The review was augmented by a
search of gray literature, clinical trials and industry market research databases, as
well as relevant congress proceeding documents. Articles were screened for rele-
vance and included if they incorporated elements of HOR outcomes, cost drivers,
cost-effectiveness, or adoption drivers. RESULTS:The literature documents tangible
advantages of an HOR approach from clinical, treatment facility and payer perspec-
tives. For example, the data suggest that enabling interventional radiologists and sur-
gical specialists to collaborate in real timemay decrease required OR treatment times
by almost 30%. Other HOR primary cost drivers are associated with room installation,
resource use efficiency, and infection control. Direct comparative data, however, is
lacking in key areas. CONCLUSIONS: Our data suggests that there are clear work-
flow, clinical, and economic benefits to adopting hybrid operating rooms and pro-
cedures. Health care decision makers will benefit from detailed reviews of HOR
clinical and economic value to determine appropriate reimbursement schemes as
well as to inform investment decisions. More research is needed to establish the
appropriate approach to compare HOR versus segregated approaches.
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OBJECTIVES: According to 2010 Bureau of National Health Insurance, Department
of Health in Taiwan, drugs costs accounted for a large proportion in health care
expenditures. On the other hand, many drugs are discarded every day from the
ShuangHoHospital drug’s recycling bins. Some of themare high-priced, unopened
and unused such as Spiriva®, Plavix®, etc. It shows that among all of the health
insurance reimbursements for medications, 25% discarded. This study is to ana-
lyze the main reasons for people discarded drugs. METHODS: In order to under-
stand the possible reasons of discarding drugs, we using questionnaires for people
who may discard or has discarded drugs. At the same time, also recording the
drug’s name and its quantity in the Shuang Ho Hospital drug’s recycling bins. The
122 questionnaires were distributed, of which 112 copied were valid, 10 copied
were invalid. We used SPSS statistical software to analyze the questionnaire re-
sults. We recorded the quantity of discarded drugs in drug’s recycling bins from
Sept.26.2011 to Oct.21.2011, classified these discarded drugs into several classes.
RESULTS: According the questionnaire results, the most likely cause for people to
discard drugs can be divided into three main reasons: misconceptions (including
fear of drug’s side effects , self-withdrawal and worry about health foods may
contain bad ingredients), forget the medication and drug deterioration (including
not pay attention to the expiration date and improper preservation). The average
weight of drugs from recycling bin is 3.76 kg / day, of which gastrointestinal drugs,
cardiovascular drugs, analgesics and hypoglycemic drugs (9.49%) are the top four
classes. CONCLUSIONS:When we figure out the main reason for people discarded
drugs, we can do something to reduce the discarded drug’s quantity more effec-
tively,, and finally, drugs will not being wasted, health care insurance in Taiwan is
expected to save about NT $ 30 billion per year
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OBJECTIVES:We previously highlighted the importance of disease-specific data in
understanding growth in healthcare spending. This update presents more recent
data and decomposes the drivers of spending growth into price, utilization, and
disease prevalence changes. METHODS: US employer health care spending was
estimated using claims data from employer sponsored health plans from 2004 and
2009 (to be updated to 2010 for presentation). Claims were assigned to disease-
specific episodes using the Thomson Reuters Medical Episode Grouper (MEG). Data
were projected using sampling weights derived from the Medical Expenditure
Panel Survey and 5-year growth in spending was decomposed into growth in dis-
ease prevalence, resource consumption per disease, and medical care price level.
RESULTS:Annual spending datawere analyzed for 107 employerswith 11.5million
health plan members in 2004 and 143 employers with 18.0 million members in
2009. Over these 5 years spending permember per year grew 34% overall, 11% after
inflation adjustment. The top 50 disease categories (out of 560) accounted for 52%of
spending in 2009. Prevalence of disease-specific treatment grew for 42 of 50 cate-
gories, led by obesity (93%), renal failure (91%), and complications of medical and
surgical care (43%). Overall, growth in prevalence drove more than 90% of the
inflation-adjusted spending increase. Resource use per patient grew in 27 of the top
50 diseases, led by dyslipidemia (106%), multiple sclerosis (57%), and osteoarthritis
except spine (42%). However, other diseases showed declines and overall intensity
of resource use grew only 2% over 5 years. CONCLUSIONS:Apart frommedical care
price inflation, the major driver of growth in employer health care spending is
increased prevalence of treated disease, led by obesity and its consequences. A
secondary factor is increased intensity of resource use in those diseases targeted by
innovation in biologic therapies and surgical devices.
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OBJECTIVES: The American Recovery and Reinvestment Act of 2009 includes an
estimated $27 billion over 10 years to support adoption of electronic health records
(EHRs). This includes the Health Information Technology (HIT) for Economic and
Clinical Health Act of 2009, which promotes meaningful use of HIT through Medi-
care and Medicaid EHR Incentive Programs. In November 2011, the United States
(US) Department of Health and Human Services released a report showing adop-
tion of HIT doubled in two years. The objective of this review was to examine the
impact of EHR and computerized physician order entry (CPOE) on health care
efficiency.METHODS: A review of published original research in the United States
was conducted in PubMed for years 2007 through 2011. The number of studies
reporting efficiencies and inefficiencies, setting of care, and areas of efficiency and
inefficiency were examined. RESULTS: A total of 18 studies were reviewed: 13 EHR
or EHR/CPOE and 5 CPOE only. Settings of care included the hospital inpatient
(n6), outpatient clinic/practice (n6), emergency department (n3), surgical cen-
ter (n2), and assisted-living facility (n1). All but one study reported efficiencies
in at least one area. Efficiencies from EHR or EHR/CPOE were reported in decreased
physician/staff time (n6), increased patient volume (n3), decreased length of
stay (n3), increased provider productivity (n2), decreased tests/procedures or-
dered (n1), and decreased time to diagnosis (n1). Efficiencies from CPOE were
observed in decreased order processing/verification time (n3), decreased physi-
cian/staff time (n1), and decreased time to medication administration (n1). In-
efficiencies from one CPOE study were reported in increased prescribing time.
Three of the EHR or EHR/CPOE studies also reported inefficiencies. Some factors
that contributed to inefficiencies included complex/acute cases and the level of
EHR implementation. CONCLUSIONS: EHR implementation has the potential to
improve efficiencies in various practice settings. Further investigation iswarranted
to examine factors contributing to inefficiencies.
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OBJECTIVES: The product promotional advertisements of pharmaceutical compa-
nies in scientific journals have the advantage of reaching to highly focused group of
doctors. The specificity of these advertisements also demands for use references to
support advertising claims which creates a niche speciality, evidence based adver-
tising. The objective of the study is to assess the references pertaining to scientific
advertisements with regard to pharmacoeconomics and humanistic outcomes ev-
idence usage.METHODS: A cross sectional study was designed to assess the use of
pharmacoeconomics and humanistic evidences use in product promotional adver-
tisements in scientific journals. For the purpose of study 14 journals, published
between January, 2010 and December, 2010 which contain advertisements were
screened. These journalswere searched for advertisements and quoted references.
All the quoted references from these advertisementswere collected and examined.
The classification of references is done based on source as journal articles, books,
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websites, data on file and miscellaneous. The Journal articles were browsed in
PubMed and Google. All collected full length articles and abstracts were examined
for key worlds Pharmacoeconomic, Cost effectiveness, Cost utility, Cost minimiza-
tion, Cost benefit and quality of life by two independent reviewers. Descriptive
statistics was used for reporting the results. RESULTS: All 14 journals searched
contained 1435 advertisements of 237 brands. The total references quoted in these
advertisements were found to be 242. Of these 242 references 57.43% were from
articles published in journals, 25.2% frommiscellaneous sources and 11.15 % from
data on file. Only 4 (0.2%) references among the published research articles were
having pharmacoeconomics and humanistic outcomes research evidence.
CONCLUSIONS: The present study clearly indicates the negligible number of phar-
macoeconomics and humanistic outcomes research evidence used in advertise-
ments published in scientific journals and there is a further need to extend this
study for other mode of advertisements such as detailing aids, leave behind liter-
ature and official websites of pharmaceutical companies.
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OBJECTIVES: Few studies regarding clinical epidemiology of internal medication
errors are published in Japan. This study aims to explore the frequency and type of
internal medication errors using incident reporting. METHODS: A total of 1706
incident reports related with internal medication errors were collected and exam-
ined at a teaching hospital with 1354 beds in Japan. Frequency, type, and injury
level of internal medication error, and health care professionals involved are in-
vestigated in the internal medication use process (e.g., ordering, dispensing, tran-
scription, and administration). RESULTS: We detected a total 1706 intravenous
medication errors between January, 2006 and March, 2010. In each stage the fre-
quency of intravenous medication errors were ordering: 2 (0.1%), transcription: 2
(0.1%), dispensing: 604 (35.4%), and administration 1,061 (62.3%). And, numbers of
reports by injury level were 732 (42.9%)reports with level 1, 328 (77.8%) reports with
level 2, 26 (1.5%) reports with level 3a, 3 (0.2%) reports with level 3b, and one (0.06%)
report with level 5. Themost common type of health care professionals were nurs-
ing staff (1,072: 62.8%), pharmacist (590: 34.6%), care worker (24: 1.4%) and physi-
cian (13: 0.9%), in decreasing order. Pharmacists were much more involved in in-
ternal medication errors than in intravenous medication errors in our study.
CONCLUSIONS: Different hospitals in Japan might lead to these results, and we
believe deeper analyses can be conducted along this theme. Furthermore, it would
be very important not only for junior residents and new nursing staff, but for
newly-hired pharmacists to be taught with emphasis that the drugs indicated
above through residency and education programs have a higher tendency to be
involved with internal medication errors. The internal medication errors involved
will be discussed with specificity during our presentation.
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OBJECTIVES: Few studies regarding clinical epidemiology of medication errors are
published in Japan. This study aims to explore the frequency and type of intrave-
nous medication errors, and drugs involved using incident reporting. METHODS:
1,855 incident reports were collected and examined at a teaching hospital with
1,354 beds in Japan. Frequency, type of medication error, and type of drugs are
investigated in the medication use process, prescription/ordering, dispensing,
transcription, and administration. RESULTS:Wedetected a total 1,885 intravenous
medication errors between January, 2006 and March, 2010. In each stage the fre-
quency of intravenous medication errors were ordering/prescription: 28 (1.5%),
transcription: 3 (0.2%), dispensing: 155 (8.2%), and administration 1,699 (90.1%).The
most common type of error throughout themedication use process were omission
of drug, wrong drug, wrong dose and wrong time. And, the most common type of
drugs were central nervous system drugs, anti-diabetic drugs (insulin), and anti-
coagulant (heparin), in decreasing order. Furthermore, the most common health
care professional involved was nursing staff (1,593: 84.5%) and the next was phar-
macist (168: 8.9%). CONCLUSIONS: Different areas in Japan might lead to these
results, and we believe deeper analyses can be conducted along this theme. Nurs-
ing staff is the number one health care professionals involved in the medication
errors, given that he/she administers most medications and is the final individual
in the medication use process. Therefore, it would be very important for newly-
hired nursing staff to be taught with emphasis that the drugs indicated above
through education programs have a higher tendency to be involved with errors.
The intravenous medication errors involved will be discussed with specificity dur-
ing our presentation.
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BACKGROUND: Improving patient adherence to medication regimens is an impor-
tant public health and clinical goal. Numerous studies have shown that non-ad-
herence to medication is associated with increased hospitalization, progression of
disease, and highermortality. There aremany practical and behavioral factors that
influence non-adherence; one of the top reasons cited is patient forgetfulness.
Automated telephonic reminders are among the most common technologies used
to help improve patient medication adherence. OBJECTIVES: To evaluate the ef-
fectiveness of an automated telephonic reminder system at improving patient
adherence to medications used to treat chronic conditions. METHODS: We con-
ducted a test-control cohort analysis using administrative data from a large chain
pharmacy. The cohorts included patients with maintenance prescriptions that
were scheduled to be refilled in April 2010. The intervention group had 82,150
patients from Colorado; these patients received refill reminder calls, as needed,
over 12 months. The control group included 182,326 patients from Washington
State; these patients did not receive reminder calls. Other than location, both
groups had similar demographic characteristics. Medication adherence and persis-
tence were calculated and compared between the intervention and control groups
in a 12-month follow-up. Medication adherence was evaluated using both contin-
uous and categorical Medication Possession Ratio (MPR) measures. Clinical adher-
ence was defined as MPR80%. Medication persistence was measured as days on
therapy and percent of patients remaining on therapy. RESULTS: At 12-month
follow-up, the MPR for the intervention group was 2.4% higher than the control
group (p0.001), and the intervention group had a 2.3% higher proportion of clini-
cally adherent patients (p0.001). Persistence for the intervention group was 7.8
days higher than the control group (p0.001), and 51.3% of patients in the inter-
vention group stayed on therapy compared to 49.6% in the control group (p0.001).
CONCLUSIONS: Automated telephonic reminders significantly improved patient
adherence to medications used to treat chronic conditions.
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OBJECTIVES: This study aims to explore the role of pharmacist for patient safety
activity in Japan. METHODS: We surveyed nationwide the situation of patient
safety activities in hospitals allowed for additional costs on patient safety mea-
sures under the social insurance medical fee schedule using a questionnaire. We
send the questionnaire including 14 fields and 93 items, to targeted 2,674 hospitals
(all hospitals: 8,706 as of 1st June in 2010) in Japan, 669 hospitals responded (re-
sponse rate: 25.0%). RESULTS: In the assignment of risk manager, mean number of
full-time risk manager as a physician was 0.04  0.24. Likewise, mean number of
full-time riskmanager as a nurse and a pharmacistwere 0.88 0.96 and 0.07 0.25.
And,meannumber of incident reports filed by physicians, nurses, and pharmacists
were 17.7  44.6, 510.0  753.7, and 30.8  112.5 in FY 2007, 17.7  45.4, 579.9 
782.5, and 31.4  86.6 in FY 2008, and 20.5  57.0, 651.7  946.4, and 39.3  171.2 in
FY 2009. Mean number of full-time risk manager as a pharmacist was higher than
that as a physician, and mean number of incident reports from pharmacists was
larger than that from physicians in Japan. CONCLUSIONS: The role of pharmacists
is getting increasingly larger for securing patient safety and pharmacists at hospi-
tals are required to bemuchmore involved in patient safety activity, asmedication
errors highly accounts for adverse events and Japan is suffering from a serious
shortage of physicians. Instead, this study is required to be statistically investi-
gated with adjusting number of beds.
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OBJECTIVES: The majority of patients with multiple chronic diseases tended to
visit single hospital persistently, which accounted for 3.5% of all beneficiaries and
19.3% of covered national health insurance expenses in Taiwan. The aim of this
research was to describe the implementation of Integrated Medical Care (IMC)
services for loyal outpatients in China Medial University Hospital (CMUH) and its
two-year outcomes. METHODS: We used the pre-post study design. Those 15,311
patients whowere loyal health care users andwithmultiple chronic illnesses were
involved. Upon patients’ disease characteristics and preference, they were offered
pluralistic IMC services, including through integrated, geriatric and/or pharmaceu-
tical care clinics, in addition to via usual primary and specialty clinics, in the
outpatient units duringDecember 2009 toDecember 2011.While the integrations of
outpatient care were facilitated by the collaboration of administration focus group
and clinical care team, those severe and vulnerable patients’ medication related
problems, health care utilizations in CMUH were reviewed periodically by clinical
care team and continuously monitored by the clinical pharmacist. The differences
of medical expenditure, number of OPD visits, number of prescribed medication
(Rx) and emergency department (ED) visits in CMUH during the same period but
one-year prior (baseline) and the implementation periods were examined.
RESULTS: After two consecutive years of IMC interventions, the medical expendi-
tures and number of OPD visits per person permonthwere reduced profoundly (up
to 7.67%), while comparing to the baseline. The numbers of Rx and ED visits, how-
ever, were not greatly different. CONCLUSIONS: There were positive outcomes of
offering pluralistic IMC services toward loyal, chronically ill patients on medical
expenditures and outpatient visits. The outcomeswould bemore significant across
time if the IMC services were provided proactively toward more mild to moderate
ill patients.
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